Unlike semaglutide, tirzepatide targets both GLP-1 and GIP (gastric inhibitory polypeptide) receptors, enhancing fat metabolism and insulin sensitivity
Retrieved from [3] Novo Nordisk
20 As the degree of familial relationship increases, recurrence risk decreases: first-, second-, and third-degree relatives have 4%, 0.7%, and 0.3% risk, respectively
Amid shortages in June 2024, the World Health Organization warned of falsified semaglutides detected in Brazil, the United Kingdom and U.S
Regular body composition checks (e.g., DXA or skinfold measurements) could also be valuable
The company's own clinical testing has shown improvements in volume, firmness, elasticity, wrinkle-reduction, and hydration